<?xml version="1.0" encoding="UTF-8"?>
<ref id="b0605">
 <label>121</label>
 <element-citation publication-type="journal" id="h0605">
  <person-group person-group-type="author">
   <name>
    <surname>Zhu</surname>
    <given-names>F.C.</given-names>
   </name>
   <name>
    <surname>Guan</surname>
    <given-names>X.H.</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>Y.H.</given-names>
   </name>
   <name>
    <surname>Huang</surname>
    <given-names>J.Y.</given-names>
   </name>
   <name>
    <surname>Jiang</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Hou</surname>
    <given-names>L.H.</given-names>
   </name>
  </person-group>
  <article-title>Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial</article-title>
  <source>Lancet</source>
  <volume>396</volume>
  <issue>10249</issue>
  <year>2020</year>
  <fpage>479</fpage>
  <lpage>488</lpage>
  <pub-id pub-id-type="pmid">32702299</pub-id>
 </element-citation>
</ref>
